Wells Fargo & Company Increases Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target to $53.00

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target hoisted by analysts at Wells Fargo & Company from $50.00 to $53.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price would suggest a potential upside of 21.87% from the stock’s current price.

Other research analysts have also issued research reports about the company. Zacks Research lowered Kiniksa Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 2nd. Weiss Ratings restated a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a report on Thursday, January 22nd. Canaccord Genuity Group initiated coverage on Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, The Goldman Sachs Group increased their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $55.29.

Kiniksa Pharmaceuticals International Stock Performance

KNSA stock opened at $43.49 on Wednesday. Kiniksa Pharmaceuticals International has a one year low of $18.25 and a one year high of $49.12. The company’s fifty day moving average price is $42.93 and its 200-day moving average price is $39.69. The company has a market capitalization of $3.30 billion, a PE ratio of 58.77 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.12). The company had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The business’s revenue was up 65.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.12) earnings per share. On average, research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insider Activity

In other news, Director Barry D. Quart sold 2,690 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, February 12th. The stock was sold at an average price of $45.00, for a total value of $121,050.00. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at approximately $564,570. The trade was a 17.66% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Eben Tessari sold 12,048 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $41.56, for a total value of $500,714.88. Following the transaction, the chief operating officer directly owned 16,666 shares in the company, valued at approximately $692,638.96. This represents a 41.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 123,623 shares of company stock valued at $5,236,389 in the last ninety days. Insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the last quarter. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter worth about $31,000. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth about $32,000. Smartleaf Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals International in the fourth quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $41,000. Institutional investors own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.